Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

Ammar Almaaytah1,2 1Faculty of Pharmacy, Middle East University, Amman, Jordan; 2Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, JordanCorrespondence: Ammar Almaaytah Tel +962777658820Email aalmaaytah@meu.edu.joIntroduction: Biosimilars of monoclonal antibodies are being rap...

Full description

Bibliographic Details
Main Author: Almaaytah A
Format: Article
Language:English
Published: Dove Medical Press 2020-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
budget impact analysis
savings
rituximab
biosimilar
cost
mena
Online Access:https://www.dovepress.com/budget-impact-analysis-of-switching-to-rituximabrsquos-biosimilar-in-r-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/budget-impact-analysis-of-switching-to-rituximabrsquos-biosimilar-in-r-peer-reviewed-article-CEOR

Similar Items